Hyderabad: The United States Food and Drug Administration (USFDA) has concluded a routine inspection at Lannett Company LLC, a wholly owned step-down subsidiary of Aurobindo Pharma, with four procedural observations.

The inspection was conducted at Lannett's facility in Seymour, Indiana, USA, from August 17 to August 21, 2026.

Aurobindo Pharma disclosed the development pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, stating that the company will submit its response to the US FDA within the stipulated timeline.

According to the company's communication, the US FDA conducted the routine inspection at Lannett Company LLC, identified as a wholly owned step-down subsidiary of Aurobindo Pharma, during the five-day period.

Upon completion of the inspection, the facility received four observations. Aurobindo Pharma stated that the observations are procedural in nature and that it will respond to the US FDA within the stipulated timeline.

The company further stated that it remains committed to maintaining robust quality and compliance standards across its manufacturing facilities.

Aurobindo Pharma has therefore formally informed the stock exchanges that the routine US FDA inspection at its step-down subsidiary Lannett Company LLC's Seymour, Indiana facility has concluded with four procedural observations. The company has undertaken to submit its response to the US FDA within the stipulated timeline and continue maintaining quality and compliance standards across its manufacturing facilities.

Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .